Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Fraser

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Expert Opinion on Investigational Drugs|December 17, 2022
Icosabutate: targeting metabolic and inflammatory pathways for the treatment of NASHDavid A Fraser, Stephen A Harrison, Detlef Schuppan
Environmental Monitoring and Assessment|February 28, 2006
Collaborative science, policy development and program implementation in the transboundary Georgia Basin/Puget Sound ecosystemDavid A Fraser, Joseph K Gaydos, Erik Karlsen, et al.
Diabetes Care|March 27, 2012
The effects of long-term oral benfotiamine supplementation on peripheral nerve function and inflammatory markers in patients with type 1 diabetes: a 24-month, double-blind, randomized, placebo-controlled trialDavid A Fraser, Lien M Diep, Inger Anette Hovden, et al.
Acta Odontologica Scandinavica|February 7, 2004
Polymorphisms in an interferon-gamma receptor-1 gene marker and susceptibility to periodontitisDavid A Fraser, Bruno G Loos, Ulf Boman, et al.
Cardiology|May 11, 2016
Icosabutate, a Structurally Engineered Fatty Acid, Improves the Cardiovascular Risk Profile in Statin-Treated Patients with Residual HypertriglyceridemiaJohn J P Kastelein, Jonas Hallén, Runar Vige, et al.
International Journal of Injury Control and Safety Promotion|May 25, 2018
Ability of crime, demographic and business data to forecast areas of increased violenceDaniel A Bowen, Laura M Mercer Kollar, Daniel T Wu, et al.
Journal of Hepatology|February 12, 2025
A phase IIb randomised-controlled trial of the FFAR1/FFAR4 agonist icosabutate in MASHStephen A Harrison, Naim Alkhouri, Grisell Ortiz-Lasanta, et al.
Scientific Reports|April 20, 2025
A medium-chain fatty acid analogue prevents endotoxin liver injury in a murine modelSarah Z Wang, Thomas I Hirsch, Scott C Fligor, et al.
Journal of Hepatology|December 16, 2021
A structurally engineered fatty acid, icosabutate, suppresses liver inflammation and fibrosis in NASHDavid A Fraser, Xiaoyu Wang, Jenny Lund, et al.
Hepatology Communications|February 7, 2020
Icosabutate Exerts Beneficial Effects Upon Insulin Sensitivity, Hepatic Inflammation, Lipotoxicity, and Fibrosis in MiceAnita M van den Hoek, Elsbet J Pieterman, José W van der Hoorn, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Expert Opinion on Investigational Drugs|December 17, 2022
Icosabutate: targeting metabolic and inflammatory pathways for the treatment of NASHDavid A Fraser, Stephen A Harrison, Detlef Schuppan
Environmental Monitoring and Assessment|February 28, 2006
Collaborative science, policy development and program implementation in the transboundary Georgia Basin/Puget Sound ecosystemDavid A Fraser, Joseph K Gaydos, Erik Karlsen, et al.
Diabetes Care|March 27, 2012
The effects of long-term oral benfotiamine supplementation on peripheral nerve function and inflammatory markers in patients with type 1 diabetes: a 24-month, double-blind, randomized, placebo-controlled trialDavid A Fraser, Lien M Diep, Inger Anette Hovden, et al.
Acta Odontologica Scandinavica|February 7, 2004
Polymorphisms in an interferon-gamma receptor-1 gene marker and susceptibility to periodontitisDavid A Fraser, Bruno G Loos, Ulf Boman, et al.
Cardiology|May 11, 2016
Icosabutate, a Structurally Engineered Fatty Acid, Improves the Cardiovascular Risk Profile in Statin-Treated Patients with Residual HypertriglyceridemiaJohn J P Kastelein, Jonas Hallén, Runar Vige, et al.
International Journal of Injury Control and Safety Promotion|May 25, 2018
Ability of crime, demographic and business data to forecast areas of increased violenceDaniel A Bowen, Laura M Mercer Kollar, Daniel T Wu, et al.
Journal of Hepatology|February 12, 2025
A phase IIb randomised-controlled trial of the FFAR1/FFAR4 agonist icosabutate in MASHStephen A Harrison, Naim Alkhouri, Grisell Ortiz-Lasanta, et al.
Scientific Reports|April 20, 2025
A medium-chain fatty acid analogue prevents endotoxin liver injury in a murine modelSarah Z Wang, Thomas I Hirsch, Scott C Fligor, et al.
Journal of Hepatology|December 16, 2021
A structurally engineered fatty acid, icosabutate, suppresses liver inflammation and fibrosis in NASHDavid A Fraser, Xiaoyu Wang, Jenny Lund, et al.
Hepatology Communications|February 7, 2020
Icosabutate Exerts Beneficial Effects Upon Insulin Sensitivity, Hepatic Inflammation, Lipotoxicity, and Fibrosis in MiceAnita M van den Hoek, Elsbet J Pieterman, José W van der Hoorn, et al.
Pageof 2